How might BioCryst fare?
BioCryst, a biotech company based in Durham, N.C., has a Phase 3 readout for a hereditary angioedema trial is right around the corner. The outcome is of critical importance: If the trial succeeds, that means hundreds of millions of dollars in sales. If it fails, however, it’s back to the drug development drawing board for BioCryst.
STAT’s Adam Feuerstein lists out six things worth knowing about the trials, and about the rare, debilitating genetic disease.
No hay comentarios:
Publicar un comentario